![]() |
![]() |
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Center | Date | Time | Location |
---|---|---|---|
CDER | July 27, 2004 | 8:30 a.m. - 5 p.m. | Center for Drug
Evaluation and Research |
Agenda:
The committee will discuss new drug application (NDA) 21-677, ALIMTA (pemetrexed)
Eli Lilly, Inc., proposed indication for single-agent treatment of patients
with locally advanced or metastatic nonsmall cell lung cancer after prior chemotherapy.
Background material and meeting information will become available no later than one business day before the meeting (Simply select the appropriate committee link).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by July 20, 2004. Oral presentations from the public will be
scheduled between approximately 11 a.m. to 12 noon. Time allotted for each presentation
may be limited. Those desiring to make formal oral presentations should notify
the contact person before July 20, 2004, and submit a brief statement of the
general nature of the evidence or arguments they wish to present, the names
and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA's advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Trevelin Prysock at 301-827-7001 at least 7 days in advance of
the meeting.
Contact Person:
Johanna M. Clifford, Food and Drug Administration, Center for Drug Evaluation
and Research (HFD-21), 5600 Fishers Lane (for express delivery, 5630 Fishers
Lane, Rm. 1093) Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail:
cliffordj@cder.fda.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington,
DC area), code 3014512542. Please call the Information Line for up-to-date information
on this meeting.